A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon

Stefania Asciutti, Danilo Castellani, Elisabetta Nardi, Olivia Morelli, Mattia Clementi, Fabio Chistolini, Giorgio Gentili, Kenneth D.R. Setchell, Nancy O'Connell, Roberto Pellicciari, Carlo Clerici

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: Ursodeoxycholic acid (UDCA) is chemoprotective in animal models of colon cancer but results from clinical trials have been less impressive probably because UDCA is rapidly absorbed in the small intestine and little reaches the colon. UDCA-glutamate (Glu), a novel bile acid, was synthesized with the objective of utilizing peptide bond cleavage by brush border enzymes to enhance delivery of UDCA to the colon. Materials and Methods: Qualitative and quantitative intestinal intraluminal and fecal bile acid composition measured by mass spectrometry was determined in Fisher rats after intragastric administration of UDCA, or UDCA-Glu for 5 days. The effect of UDCA and UDCA-Glu on bile flow was studied after bile duct canulation. Results: In the small intestine, UDCA was found in higher amounts when UDCA was administered compared with UDCA-Glu (1.50±0.32 vs. 0.75±0.12 mg). By contrast, UDCA-Glu administration resulted in a greater delivery of UDCA to the colon. The fecal bile acid composition resembled that of the intraluminal colonic composition and a higher mass of UDCA (unconjugated 3.39±0.30 mg; conjugated 6.40±1.03 mg) was found in rats treated with UDCA-Glu compared to those treated with UDCA (2.27±0.11 and. 0.04±0.01 mg, respectively), establishing increased delivery of UDCA to the colon. Both bile acids similarly increased bile flow but the initial effect of UCDA was greater than that of UDCA-Glu. Conclusion: Conjugation of UDCA to glutamic acid reduces its intestinal absorption and biotransformation resulting in increased colonic delivery of UDCA. UDCA-Glu may have potential application as a pro-drug for enhancing the action of UDCA in the treatment of colonic diseases.

Original languageEnglish
Pages (from-to)4971-4979
Number of pages9
JournalAnticancer Research
Volume29
Issue number12
StatePublished - Dec 2009
Externally publishedYes

Keywords

  • Bile acids
  • Cancer prevention
  • Colon cancer
  • UDCA
  • Udca-glu

Fingerprint

Dive into the research topics of 'A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon'. Together they form a unique fingerprint.

Cite this